Marshall Tyler, Hancock Myles, Kinnard Elizabeth N, Olson Karin, Abba-Aji Adam, Rittenbach Katherine, Stea Jonathan N, Tanguay Robert, Vohra Sunita
Department of Psychiatry, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
J Subst Abuse Treat. 2022 Apr;135:108646. doi: 10.1016/j.jsat.2021.108646. Epub 2021 Nov 12.
Shared decision-making (SDM) is an approach to clinical decision-making that includes patients' values and preferences during health-related decisions. Previous research suggests that SDM may be beneficial in the treatment of substance use disorders; however, the impact of SDM in the treatment of opioid use disorder (OUD) remains unclear.
To identify relevant peer-reviewed literature related to SDM in the treatment of adults with OUD, and to summarize the main findings according to patient outcomes.
The research team conducted a scoping review. The team searched five electronic health databases from database inception until September 2019 using MeSH and keywords related to SDM. The team included only peer-reviewed studies where adults (≥18 years) with OUD were provided a choice and/or allowed input into their treatment plan. Two independent reviewers screened, extracted, and assessed the quality of included studies.
Fourteen studies (n = 1748 participants) met inclusion criteria, including seven randomized controlled trials, three non-randomized controlled trials, two observational studies, and one qualitative study. Treatment options included: patient regulated methadone dosing vs. fixed dosing (n = 4 studies), optional vs. mandatory counseling (n = 4 studies), home vs. office buprenorphine inductions (n = 2 studies), and inpatient vs. outpatient treatment (n = 1 study). None of the studies measured SDM with a validated instrument. Seven of 14 studies reported at least one improved patient outcome.
The review found few studies that explored whether providing treatment options and/or encouraging participation in decision-making are beneficial for adults with OUD. Preliminary evidence suggests that SDM may be promising for this population. However, the field needs more research on person-centered care and SDM.
共同决策(SDM)是一种临床决策方法,在与健康相关的决策过程中纳入患者的价值观和偏好。先前的研究表明,共同决策可能有助于物质使用障碍的治疗;然而,共同决策在阿片类物质使用障碍(OUD)治疗中的影响仍不明确。
识别与成人阿片类物质使用障碍治疗中共同决策相关的同行评审文献,并根据患者结局总结主要研究结果。
研究团队进行了一项范围综述。团队从数据库建立至2019年9月,使用医学主题词(MeSH)和与共同决策相关的关键词,检索了五个电子健康数据库。团队仅纳入了同行评审研究,这些研究中为患有阿片类物质使用障碍的成人(≥18岁)提供了选择和/或允许其参与治疗计划的制定。两名独立评审员对纳入研究进行筛选、提取并评估质量。
14项研究(n = 1748名参与者)符合纳入标准,包括7项随机对照试验、3项非随机对照试验、2项观察性研究和1项定性研究。治疗选项包括:患者自主调节美沙酮剂量与固定剂量(n = 4项研究)、选择性咨询与强制性咨询(n = 4项研究)、在家中与在办公室进行丁丙诺啡诱导(n = 2项研究)以及住院治疗与门诊治疗(n = 1项研究)。没有一项研究使用经过验证的工具来衡量共同决策。14项研究中的7项报告了至少一项改善的患者结局。
该综述发现,很少有研究探讨提供治疗选项和/或鼓励参与决策对患有阿片类物质使用障碍的成人是否有益。初步证据表明,共同决策对该人群可能有前景。然而,该领域需要更多关于以患者为中心的护理和共同决策的研究。